Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | LSS | P48449 | 1/20 | 0.57 |
| ▸ | NAMPT | P43490 | 4/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.54 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.52 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CNR1 | P21554 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23747769 | 0.91 | RAB9A (0.56) | RAB9APOLBNPC1LSSNAMPT | |
| SCHEMBL26102016 | 0.90 | RAB9A (0.57) | RAB9APOLBNPC1LSSNAMPT | |
| SCHEMBL23747558 | 0.87 | RAB9A (0.60) | RAB9APOLBNPC1LSSNAMPT | |
| SCHEMBL26101879 | 0.86 | RAB9A (0.55) | RAB9APOLBNPC1LSSNAMPT | |
| SCHEMBL26547059 | 0.86 | RAB9A (0.55) | RAB9APOLBNPC1LSSNAMPT | |
| SCHEMBL23747313 | 0.85 | CHRM1 (0.62) | RAB9APOLBNPC1LSSNAMPT | |
| SCHEMBL23747684 | 0.85 | CHRM1 (0.65) | RAB9APOLBNPC1LSSNAMPT | |
| SCHEMBL23728210 | 0.85 | SMN1; SMN2 (0.61) | RAB9APOLBNPC1NAMPTMEN1 | |
| SCHEMBL26134296 | 0.84 | CHRM1 (0.67) | RAB9APOLBNPC1LSSNAMPT | |
| SCHEMBL26546714 | 0.84 | RAB9A (0.55) | RAB9APOLBNPC1LSSNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2021159015-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133132-A1 | NAMPT MODULATORS | NAMPT, MC4R, SIRT1 | RAB9A 807/4885POLB 4018/4885NPC1 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.